DoseCraft
VapeHeatLabCBDV
Cannabidivarin, a non-psychoactive cannabinoid being researched for potential anticonvulsant and neuroprotective effects.
Cannabidivarin, or CBDV, is a non-psychoactive cannabinoid closely related to CBD but with a shorter side chain. Found naturally in certain cannabis cultivars, CBDV is present in higher concentrations in landrace indica strains from northwest India and Nepal. It has become a focus of pharmaceutical research for neurological conditions.
Research Highlights
GW Pharmaceuticals (now part of Jazz Pharmaceuticals) has conducted clinical trials investigating CBDV for epilepsy, particularly in conjunction with their existing CBD-based drug Epidiolex. Preclinical research has shown CBDV may reduce nausea through interaction with 5-HT1A serotonin receptors and TRPV1 channels. Studies have also explored CBDV for Rett syndrome and autism spectrum disorders, though these investigations remain in early stages. A 2019 study in the Journal of Psychopharmacology found that CBDV altered brain connectivity patterns in adults with autism.
Availability
CBDV is not yet widely available as a standalone consumer product, though it appears naturally in certain hemp-derived full-spectrum extracts. As research progresses and demand grows, some companies have begun offering CBDV-enriched products. For consumers interested in minor cannabinoids, checking detailed lab reports for CBDV content can help identify products that contain meaningful amounts of this compound.